Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
外泌体驱动的癌症进展免疫调节机制
基本信息
- 批准号:10671960
- 负责人:
- 金额:$ 4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-23 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesBasic ScienceBedsBiotinBlocking AntibodiesBypassCancer ModelCell CommunicationCell LineCell physiologyCell surfaceCellsClinical SciencesDataDisease remissionDistalDistantFosteringGoalsHealthHumanImmuneImmune checkpoint inhibitorImmune systemImmunityImmunologicsImmunosuppressionImmunotherapyIn VitroInjectionsIntegral Membrane ProteinKnowledgeLabelLeadLigandsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of pancreasMalignant neoplasm of prostateManipulative TherapiesMass Spectrum AnalysisMembrane ProteinsMemoryMicroscopyMissionModelingMonoubiquitinationMusPD-L1 blockadePathway interactionsPatientsProteinsProteomicsPublic HealthRenal carcinomaResearchResearch PersonnelResistanceRoleSamplingSiteSorting - Cell MovementStructureSurfaceT-Cell ActivationT-LymphocyteTestingTherapeuticTherapeutic antibodiesTranslational ResearchTumor ImmunityTumor-DerivedUnited States National Institutes of HealthVaccinesVariantVisionanti-PD-1anti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 therapyanti-tumor immune responseantigen-specific T cellsbasecancer carecancer cellcancer therapycancer typecell typecheckpoint therapydifferential expressiondraining lymph nodeexosomeexperimental studyimmune checkpointimmunoregulationimprovedin vitro Modelin vivo Modelinsightmelanomamutantneoplastic cellnovel strategiesnovel therapeutic interventionpersonalized cancer therapyprogrammed cell death ligand 1programmed cell death protein 1protein functionpublic health relevancereceptorrefractory cancerresponsesuccesstherapy resistanttumortumor progression
项目摘要
PROJECT ABSTRACT:
Antibodies against the immune checkpoint proteins PD-L1 and PD-1 have revolutionized cancer therapeutics
resulting in durable remissions in many patients previous considered incurable. However, a majority of patients
remain resistant and cancer types can vary greatly in their response rates. Thus, there is an urgent need to
understand the variation in response in order to improve cancer care. This proposal brings together a team of
investigators with complementary expertise in basic, translational, and clinical science who share the long-term
goal of finding novel approaches to categorize and personalize cancer treatments. Recent results from the
investigators suggest a major role for the packaging of immune checkpoint proteins in exosomes underlying the
variation in responses to immune checkpoint inhibitors among patients. Specifically, varying amounts of PD-L1
can be trafficked to exosomes, which in turn can act at a distance to suppress anti-tumor T cell function, enabling
tumor progression, even in models resistant to anti-PD-L1 treatments. The objective of this proposal is to build
on these findings by focusing on the mechanism of exosomal PD-L1 packaging, action, and resistance to
therapeutic antibodies. In particular, the proposal will test the overall hypothesis that tumor cells can selectively
package PD-L1 into exosomes that suppress T cell priming at distal sights in a fashion that is distinct from the
cell-cell interactions of PD-L1 and PD-1 normally seen in the tumor bed. The hypothesis is premised on extensive
preliminary data using in vitro and in vivo models showing that the relative fraction of PD-L1 packaged in
exosomes versus retained in cells varies between cell lines, that suppression of exosomal PD-L1 can result in
long-term systemic anti-tumor immunity, and that exosomal PD-L1 is resistant to anti-PD-L1 antibodies. To test
the overall hypothesis, the following aims are proposed: 1) Uncover mechanisms underlying the selective
packaging of PD-L1 into exosomes, 2) Evaluate the mechanistic basis of exosomal PD-L1’s impact on systemic
immunity, 3) Dissect how exosomal PD-L1 interacts with and regulates its target cells. In aim 1, structure/function
and proteomic approaches are proposed to identify the regulators of PD-L1 packaging into exosomes.
Furthermore, associations between expression of these factors and resistance to therapy will be evaluated using
primary patient samples. In aim 2, mouse-based immunological approaches and patient samples will be used to
determine where in the immune axis exosomal PD-L1 functions. Uncovered insights will then be used to develop
a novel therapeutic approach to enhance the anti-tumor immune response. In aim 3, microscopy and functional
studies in in vitro models along with association studies with patient samples will be used to determine how
exosomal PD-L1 interacts with its target cells potentially explaining its resistance to antibodies. The proposal is
highly significant in that it is expected to provide new fundamental knowledge that can be used to identify and
treat the large fraction of patients resistant to current immune therapies. While this proposal focuses on a subset
of cancer models with a particular emphasis on prostate cancer, the paradigms uncovered are expected to be
relevant across most if not all tumor types.
项目摘要:
针对免疫切除蛋白PD-L1和PD-1的抗体已彻底改变了癌症治疗
导致许多先前被认为无法治愈的患者持续恢复。但是,大多数患者
保持耐药性,癌症类型的反应率可能差异很大。那迫切需要
了解以改善癌症护理的响应差异。该提议汇集了一个团队
具有基础,翻译和临床科学专业知识的研究人员,他们共享长期的
寻找新颖的方法来对癌症治疗进行分类和个性化。来自
研究人员建议在外泌体中包装免疫检查点蛋白包装的主要作用
患者对免疫切除剂抑制剂的反应变化。具体而言,大量的PD-L1数量
可以将外泌体运输到外泌体,而外泌体可以在距离抑制抗肿瘤T细胞功能的距离上起作用,从而使
肿瘤进展,即使在抗抗PD-L1处理的模型中也是如此。该提议的目的是建立
在这些发现上,通过关注外泌体PD-L1包装的机制,动作和对
治疗性抗体。特别是,该提案将检验肿瘤细胞可以选择性的总体假设
包装PD-L1进入外泌体,以与不同的方式抑制T细胞启动的T细胞启动
PD-L1和PD-1的细胞细胞相互作用通常在肿瘤床中可见。该假设以广泛的形式前提
使用体外和体内模型的初步数据表明,包装在包装中的PD-L1的相对分数
外泌体与保留在细胞之间的外泌体在细胞系之间有所不同,外泌体PD-L1的抑制可能会导致
长期全身性抗肿瘤免疫组织化学,外泌体PD-L1对抗PD-L1抗体具有抗性。测试
总体假设提出了以下目的:1)发现选择性的基础机制
PD-L1将PD-L1包装到外泌体中,2)评估外osomemal PD-L1对系统性影响的机械基础
免疫,3)剖析外泌体PD-L1如何与其靶细胞相互作用并调节其靶细胞。在AIM 1中,结构/功能
并提出了蛋白质组学方法来识别PD-L1包装的调节剂中的外泌体。
此外,将使用这些因素的表达与对治疗的抵抗力之间的关联。
主要患者样品。在AIM 2中,基于小鼠的免疫方法和患者样本将用于
确定在免疫轴外泌体PD-L1功能中的位置。然后将使用发现的见解来发展
一种新型的热方法来增强抗肿瘤免疫反应。在AIM 3中,显微镜和功能
研究体外模型的研究以及与患者样本的关联研究将用于确定如何
外泌体PD-L1与其靶细胞相互作用,可能解释其对抗体的抗性。该提议是
非常重要的是,预计将提供可用于识别和
治疗大量患者对当前免疫疗法的抗性。虽然该提议着重于子集
在特别强调前列腺癌的癌症模型中,发现的范例将是
在大多数肿瘤类型中相关。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert Blelloch其他文献
Robert Blelloch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert Blelloch', 18)}}的其他基金
Establishing the development basis for the morphological and functional asymmetry of the human chorion
建立人类绒毛膜形态和功能不对称的发育基础
- 批准号:
10673397 - 财政年份:2023
- 资助金额:
$ 4万 - 项目类别:
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
外泌体驱动的癌症进展免疫调节机制
- 批准号:
10381379 - 财政年份:2021
- 资助金额:
$ 4万 - 项目类别:
Iteratively redefining developmental potential through poised enhancers
通过稳定的增强剂迭代地重新定义发展潜力
- 批准号:
9753014 - 财政年份:2017
- 资助金额:
$ 4万 - 项目类别:
Rewiring of the pluripotency enhancer network during early mammalian development
早期哺乳动物发育过程中多能性增强子网络的重新布线
- 批准号:
9403957 - 财政年份:2017
- 资助金额:
$ 4万 - 项目类别:
Rewiring of the pluripotency enhancer network during early mammalian development
早期哺乳动物发育过程中多能性增强子网络的重新布线
- 批准号:
9754842 - 财政年份:2017
- 资助金额:
$ 4万 - 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
- 批准号:
8582076 - 财政年份:2013
- 资助金额:
$ 4万 - 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
- 批准号:
8923178 - 财政年份:2013
- 资助金额:
$ 4万 - 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
- 批准号:
9122348 - 财政年份:2013
- 资助金额:
$ 4万 - 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
- 批准号:
8713966 - 财政年份:2013
- 资助金额:
$ 4万 - 项目类别:
In Vivo Regulated Release and Function of Extracellular Small RNAs
细胞外小 RNA 的体内调节释放和功能
- 批准号:
9519087 - 财政年份:2013
- 资助金额:
$ 4万 - 项目类别:
相似国自然基金
人源化小鼠筛选猴痘抗体及机制研究
- 批准号:82373778
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
抗HTNV抗体mRNA修饰MSC在肾综合征出血热治疗中的作用研究
- 批准号:82302487
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人和小鼠中新冠病毒RBD的免疫原性表位及其互作抗体的表征和结构组学规律的比较研究
- 批准号:32371262
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure
m6A-RNA 甲基化在记忆形成和回忆中的作用及其对早期铅暴露对长期结果的影响
- 批准号:
10658020 - 财政年份:2023
- 资助金额:
$ 4万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 4万 - 项目类别:
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 4万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 4万 - 项目类别:
De novo design of a generalizable protein biosensor platform for point-of-care testing
用于即时测试的通用蛋白质生物传感器平台的从头设计
- 批准号:
10836196 - 财政年份:2023
- 资助金额:
$ 4万 - 项目类别: